To help keep up with the dynamic landscape in nuclear medicine fueled by theranostics, AuntMinnie offers the Radiopharmaceutical Therapy (RPT) Tracker. Reach us at [email protected] with new entries or updates.
Last Updated: September 2, 2026 ↓
Latest News: September 2, 2026 ▾
AuntMinnie Coverage
Telix completes enrollment in BiPASS study
September 2, 2026 · Telix · Illuccix/Gozellix (Ga-68 PSMA-PET)
Norroy secures FDA breakthrough therapy, fast-track status for PET imaging agent
August 19, 2026 · Norroy Biosciences · Ga-68 NYM096
Curium to acquire Lantheus in $8 billion deal
August 4, 2026 · Curium · Lantheus
Novartis secures expanded approval for Pluvicto
August 4, 2026 · Novartis · Pluvicto
Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer
July 23, 2026 · Novartis · Pluvicto
AdvanCell raises $315M for targeted alpha therapy
July 15, 2026 · AdvanCell · ADVC001
Blue Earth, UCL dose first patient in Ac-225 PSMA prostate trial
July 9, 2026 · Blue Earth Therapeutics · Ac-225 rhPSMA-10.1
GE Healthcare, Mayo Clinic begin new theranostics trial in Minnesota
July 8, 2026
Molecular Partners, Orano Med dose first patients in MP0712 trial
July 2, 2026 · Molecular Partners · MP0712
Novel SST2-PET tracer shows promise in patients with NETs
June 25, 2026 · Nuclidium · Cu-61 NODAGA-LM3
New PET tracer shows promise for guiding pancreatic cancer therapy
June 19, 2026 · Nihon Medi-Physics · Zr-89 NMK89
New immuno-PET tracer shows promise in prostate cancer
June 15, 2026 · Fortis Therapeutics · Zr-89 DFO-YS5
RadioMedix wins FDA ANDA approval for Ga-68 PSMA-11 PET imaging agent
June 10, 2026 · RadioMedix · Ga-68 PSMA-11
ITM to present COMPETE trial dosimetry data at SNMMI 2026
June 4, 2026 · ITM · Edotreotide
| Company | Drug (Isotope) / Imaging Agent | Indication(s) / Target | Phase |
|---|
No programs match your filters.
